Virtual Challenging Case Clinic: Multiple Myeloma

  • Engage with leading experts to strategize on therapeutic options for your patients
  • Stay up to date on novel agents approved for the treatment of multiple myeloma, and assess recommended sequencing of therapy


Course Director

Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia


  • Welcome, Introductions, and Pre-session Survey
  • General Disease State and Treatment Guidelines
  • Expert Insights: Faculty-submitted cases
  • Case Presentation, Polling Questions, and Discussion
  • Q&A
  • Conclusion and Post-session Survey

Upcoming Webinars

April 21, 2021

CAR T Cells for MM

Nina Shah, MD
UCSF, San Francisco, California

June 16, 2021

Updates from ASCO and EHA

Jonathan Kaufman, MD
Winship Cancer Institute of Emory University, Atlanta, Georgia

August 18, 2021

Agents Targeting BCMA


October 20, 2021

Aligning Induction Therapy for Each Patient

Saad Usmani, MD, FACP
Atrium Health, Charlotte, North Carolina


December 15, 2021

Updates from ASH

Krina Patel, MD, MSc
MD Anderson Cancer Center, Houston, Texas


February 16, 2022

MM-associated AL Amyloidosis

Shaji Kumar, MD
Mayo Clinic, Rochester, Minnesota


Recordings From Previous Webinars

Updates from ASH and Year in Review

Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on January 20, 2021

Emerging Therapeutic Options: What’s On the Horizon?

Adam Cohen, MD
University of Pennsylvania | Philadelphia, Pennsylvania
Broadcast on November 18, 2020

Treating Relapsed/Refractory MM: Sequencing of Therapies

Paul G. Richardson, MD
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on September 16, 2020

Updates from ASCO and EHA

Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas
Broadcast on July 15, 2020

Maintenance Therapy Approaches

Nina Shah, MD
University of California, San Francisco | San Francisco, California
Broadcast on May 20, 2020

Newly Diagnosed MM Treatment Options

Peter Voorhees, MD
Levine Cancer Institute | Charlotte, North Carolina
Broadcast on March 18, 2020

Target Audience
The target audience for this activity is clinicians who treat patients with multiple myeloma: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
Learning Objectives
  • Evaluate best available evidence regarding the treatment of patients with multiple myeloma
  • Assess the implications of emerging clinical trial data regarding multiple myeloma treatment approaches
  • Develop strategies to address complicated multiple myeloma cases
Continuing Education
The University of Nebraska Medical Center, Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education designates this activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Disclosure Statement
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality. All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

This activity is supported by independent educational grants from Bristol Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides.

Contact Us

Questions? Please contact Bio Ascend by phone: 888-476-9129 or email:!